Breakthrough promises ultra-high-resolution spectroscopy with wide variety of applications By Jed Thomas A new study ...

When an ordinary beam of neutrons strikes the team’s silicon grating, the millions of scored lines on the grating convert the ...

Onctura commences randomized Phase I/II study in non-small cell lung cancer First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have ...

Superbooth 25: Korg has been teasing an ‘acoustic synthesis’ product for a couple of years now. We first got wind of it at ...

Updated results from the Phase III ELATIVE trial reveal Iqirvo (elafibranor) significantly reduced fatigue in patients with ...

BHVN's Troriluzole awaits pivotal FDA approval in 2025, backed by $600M funding. Explore its diverse pipeline and promising ...

Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET. Company Participants. Bernie Hertel - Head of Investor Relations Punit Dhillon - Presi ...

Chirality—the property of an object that is distinct from its mirror image—has long captivated scientists across biology, ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...